ENDRA Life Sciences
NDRA
1 hedge funds and large institutions have $122K invested in ENDRA Life Sciences in 2017 Q4 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
841% more capital inflows, than outflows
Capital inflows: $113K | Capital outflows: $12K
0.55% more ownership
Funds ownership: 0.1% → 0.65% (+0.55%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Winslow Evans & Crocker
Boston,
Massachusetts
|
+$113K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$12K |
NDRA Hedge Fund Activity: Q4 2017 in Review
1 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in ENDRA Life Sciences (NDRA) for Q4 2017, worth a combined $122K — up 918% from $12K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new NDRA positions and 0 closed out — a net gain of 1 holder — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Winslow Evans & Crocker, opening a new position worth an estimated $113K. The largest seller was UBS Group, cutting an estimated $12K.
- 1 institutional investor held ENDRA Life Sciences (NDRA) as of Q4 2017, up from 0 in Q3 2017.
- Funds reported $122K of ENDRA Life Sciences stock for Q4 2017, up 918% quarter-over-quarter.
- 1 fund opened new ENDRA Life Sciences positions in Q4 2017 and 0 closed out, a net change of +1 holder.
- The largest ENDRA Life Sciences buyer in Q4 2017 was Winslow Evans & Crocker, an estimated $113K added.
- The largest ENDRA Life Sciences seller in Q4 2017 was UBS Group, an estimated $12K sold.
Based on aggregated 13F filings for Q4 2017.